Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Alnylam Pharmaceuticals (ALNY US)
Watchlist
75
Analysis
Health Care
•
United States
Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
S&P 500 INDEX
•
28 Nov 2019 06:30
U.S. Equity Strategy: Upgrading Health Care to Overweight
Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...
Vermilion Research
Follow
380 Views
Share
bullish
•
Thematic (Sector/Industry)
•
26 Jun 2018 15:55
Trade Risks Start to Impact, as China Biotech Ambitions Grow…
Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...
Sean Maher
135 Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Jan 2018 09:35
Human Longevity
At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...
KIS Capital Partners
527 Views
Share
bullish
•
Thematic (Sector/Industry)
•
28 Nov 2017 16:52
Drugs Evolving Into 'Biological Software' to Boost Moribund Pharma Sector?
The global pharma and biotech sector has underperformed by about four points this year, and five over three years – the divergence with other...
Sean Maher
227 Views
Share
bullish
•
S&P 500 INDEX
•
06 Sep 2017 23:22
U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight
Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...
Vermilion Research
Follow
491 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3
x